DECASPRAY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Decaspray, and what generic alternatives are available?
Decaspray is a drug marketed by Merck and is included in one NDA.
The generic ingredient in DECASPRAY is dexamethasone. There are thirty-nine drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the dexamethasone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Decaspray
A generic version of DECASPRAY was approved as dexamethasone by XSPIRE PHARMA on April 28th, 1983.
Summary for DECASPRAY
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 115 |
Clinical Trials: | 7 |
Patent Applications: | 4,556 |
Formulation / Manufacturing: | see details |
DailyMed Link: | DECASPRAY at DailyMed |
Recent Clinical Trials for DECASPRAY
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Multiple Myeloma Research Consortium | Phase 2 |
Millennium Pharmaceuticals, Inc. | Phase 2 |
Washington University School of Medicine | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for DECASPRAY
US Patents and Regulatory Information for DECASPRAY
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck | DECASPRAY | dexamethasone | AEROSOL;TOPICAL | 012731-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for DECASPRAY
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
AbbVie Deutschland GmbH & Co. KG | Ozurdex | dexamethasone | EMEA/H/C/001140 Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO).Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis.Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy. |
Authorised | no | no | no | 2010-07-26 | |
THERAVIA | Neofordex | dexamethasone | EMEA/H/C/004071 Treatment of multiple myeloma. |
Authorised | no | no | no | 2016-03-16 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |